Amisulpride
Severe
Database
Drug interaction classified as: antagonism
Source: DDInter
Drug reference
Rotigotine
Dopamine Agonist · Antiparkinsonian Agent
Also known as NEUPRO
Dopamine AgonistAntiparkinsonian Agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
3 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- AmisulprideSevereDatabaseDDInter
- DextropropoxypheneSevereDatabaseDDInter
- Sodium OxybateSevereDatabaseDDInter
Mechanism
Rotigotine preferentially binds to D2 and D3 receptors and has much lower affinity for D1 receptors. Additionally, rotigotine acts as an agonist at 5-HT1A and 5-HT2 receptors and an antagonist at α2 adrenergic receptors.
Indications
Parkinson diseaseEarly Parkinson diseaseDystonias and other involuntary movementsParkinson's diseaseRestless leg syndrome (RLS)Treatment of PDRestless legs syndrome
Dosing
- Adult
- Treatment is usually started with the 2 mg/24 hours patch and titrated weekly as necessary by increasing the patch size to 4 mg/24 hours and then to 6 mg/24 hours.
- Max dose
- 6 mg/24 hours
Pharmacokinetics
Duration
24 hours
Side effects
Common
Application site reactionshallucinosisconfusionnauseaorthostatic hypotensionfatiguesomnolence
Serious
- Serious application site reactions
- impulse control disorder (ICD)
Drug interactions
Dextropropoxyphene
Severe
Database
Clinical effect not specified
Source: DDInter
Sodium Oxybate
Severe
Database
Clinical effect not specified
Source: DDInter
9 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Acute coronary syndrome in chronic kidney disease
CSI · Cardiology · 2020
Empirical antimicrobial use in common syndromes
ICMR · Infectious Diseases · 2019
Coeliac disease
OTHER · Gastroenterology · 2016
Inflammatory bowel disease
OTHER · Gastroenterology · 2015
Chronic kidney disease — assessment and management
KDIGO · Nephrology · 2024
Other Dopamine Agonist drugs
Ask House about Rotigotine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF·Verified: 2026-05-10 · House clinical team